Asthma Clinical Trial
Official title:
Fresno Asthmatic Children's Environment Study
Asthma can be caused by many factors, including mold, pollen, and other airborne pollutants. The purpose of this study is to evaluate the effect that air pollution has on the long-term severity of asthma symptoms and lung function in children.
Asthma prevalence has steadily increased in the United States since the early 1980's;
currently more than 20 million people are diagnosed with asthma, including 9 million
children. Asthma can be caused by many factors, including pollen, dust, tobacco smoke, and
other allergens. Research has shown that even short-term increases in daily levels of air
pollution can trigger an increase in asthma symptoms in some individuals. More research is
needed to determine how short-term increases in air pollution affect the severity of asthma
later in life. The Environmental Protection Agency (EPA) has constructed research monitoring
stations, known as Supersites, to advance the understanding of the effect of airborne
pollutants on the health of individuals. Data collected from the Supersites provide
important information regarding air pollution and air quality levels. This study will use
air pollution measurements obtained from the Fresno, California Supersite to monitor
participants' exposure to air pollution. The purpose of the study is to determine if
children who experience a worsening of asthma symptoms due to an increase in air pollution
have greater long-term asthma severity and decreased lung function compared to children who
do not experience a worsening of symptoms when exposed to air pollution.
This study will enroll children with asthma who live within 20 kilometers of the EPA
Supersite in Fresno, California. Participants will have study visits twice a year for up to
2 ½ years. At study entry, participants will undergo a skin prick allergy test and complete
a dietary questionnaire. At each study visit, a respiratory illness questionnaire will be
completed, and participants will undergo spirometry tests to measure lung function. In
addition to the twice yearly visits, participants will take part in three 14-day sessions
each year, during which daily diaries will be completed and spirometry will be performed
twice a day. Study staff will gather detailed air pollution information from the Supersite,
mobile monitoring trailers, and inside and outside the participants' homes.
Beginning in May 2006, participants will take part in only one study visit and two 14-day
sessions each year. Air pollution measurements will be obtained from only the Supersite. To
estimate daily exposure to air pollution, all participants will wear a global positioning
system (GPS) device and complete daily activity diaries for 5 days during the school year.
Fifty participants who have demonstrated compliance with study procedures will be selected
to also wear the GPS devices for 5 days during the summer months.
The study completion date listed in this record was obtained from the "Completed Date"
entered in the Query View Report System (QVR).
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|